The Broker Compensation Wars

The broker and agent channel is where Medicare policy meets the kitchen table. Compensation rules, enforcement actions, and regulatory posture determine who sells what to whom and on what terms. In 2025 and 2026, three forces collided: CMS tightened broker compensation and marketing rules under the Biden administration, DOJ brought a blockbuster False Claims Act action against three major insurers and three major brokerages, and a federal court struck down parts of the compensation regulatory framework, all while the new administration signaled a deregulation pivot through the CY 2027 proposed rule. The result is a broker ecosystem operating under simultaneous deregulatory signals from CMS, active enforcement from DOJ, and legal uncertainty from the courts.

The Regulatory Rulemaking Arc

#

The Biden-era CMS built a regulatory framework for broker and agent oversight in two successive rulemaking cycles. The CY 2025 rule established broker compensation caps, setting a national fixed compensation amount for initial enrollments into MA or Part D plans. It imposed documentation requirements on plan-agent contracting and established standards designed to prevent the compensation structure from functioning as a plan competition tool that distorted enrollment toward high-commission plans rather than plans that best fit the beneficiary’s needs.

The CY 2026 rule added further guardrails: restrictions on marketing materials, call recording requirements for enrollment interactions, scope of appointment enforcement to ensure beneficiaries consented to discussing specific plan types before the sales interaction began, expanded plan responsibility for monitoring downstream agent and broker activities, and limitations on the distribution of personal beneficiary data by Third Party Marketing Organizations. These rules responded to documented abuses in which beneficiaries were enrolled in plans without their knowledge or consent, switched between plans repeatedly for commission generation, and contacted aggressively through unsolicited calls driven by lead generation data.

The CY 2027 proposed rule (CMS-4212-P), released November 25, 2025 under the Oz CMS, moves in the opposite direction. It proposes to relax several of the 2023 and 2024 marketing oversight measures, including removing time and manner restrictions on marketing by MA plan agents at educational events, reducing record retention requirements, and easing certain compliance monitoring obligations that plans bear for their downstream marketing partners. The deregulation theory is that broker activity is a market function, that excessive regulation constrains beneficiary access to plan information, and that the prior administration’s rules imposed compliance costs that ultimately reduced the number of agents willing to sell MA, limiting beneficiary choice.

What remains in place regardless of the proposed rollback is significant. The statutory framework governing broker compensation in Medicare is distinct from the regulatory overlay CMS added. Federal anti-kickback statute prohibitions on payments that induce referrals of federal healthcare program beneficiaries do not depend on CMS rulemaking and are not affected by the proposed rule. The FCA’s prohibition on false claims arising from kickback-tainted enrollments operates independently. A plan or broker that relies on CMS deregulation as license to return to pre-2023 compensation practices without examining its FCA and AKS exposure is making a compliance error that the DOJ action makes concrete.

The eHealth DOJ Action

#

On May 1, 2025, DOJ filed a False Claims Act complaint against Aetna, Elevance Health (formerly Anthem), and Humana, along with Medicare Advantage brokerages eHealth, GoHealth, and SelectQuote. The complaint, filed in the U.S. District Court for the District of Massachusetts, originated from a whistleblower action filed in November 2021 by Andrew Shea, a former eHealth senior vice president of marketing. DOJ intervened and took over the case.

The allegations are sweeping. DOJ claims that from 2016 through at least 2021, the three insurers paid hundreds of millions of dollars in payments labeled as “marketing,” “co-op,” or “sponsorship” fees to the three brokerages. DOJ alleges these payments were disguised kickbacks paid in exchange for preferential enrollment steering: the brokerages directed Medicare beneficiaries toward whichever insurer’s plans paid the largest fees, regardless of plan quality or suitability for the individual beneficiary. The complaint cites internal communications in which executives acknowledged the nature of the arrangements. In one cited exchange, an eHealth executive discussed a Humana “marketing” agreement that paid $15 million annually for a website generating minimal enrollments, joking that CMS would not figure it out. An eHealth executive described Aetna’s marketing payment model as not compliant.

The complaint goes further. DOJ alleges that Aetna and Humana conspired with brokers to discriminate against Medicare beneficiaries with disabilities, whom the insurers perceived as more costly to cover. The insurers allegedly threatened to withhold kickback payments unless brokers enrolled fewer disabled beneficiaries. In response, brokers allegedly rejected referrals, screened calls, and used data filters and call-routing strategies to divert disabled individuals away from those plans. The complaint cites specific instances, including a cancer patient switched from Original Medicare into a managed care plan by a brokerage, only to face $17,000 in treatment costs that would have been covered under the prior arrangement.

A hearing on a joint motion to dismiss was held on January 21, 2026. A decision from the District of Massachusetts is expected in the coming months. All six defendants have denied the allegations and pledged to defend vigorously.

The implications extend beyond the named parties. The DOJ action establishes that broker steering through disguised compensation is an active enforcement theory, backed by FCA treble damages and per-claim penalties. Every MA plan that pays marketing, sponsorship, or administrative fees to brokerages above the regulated commission structure now operates under the shadow of this case. The compliance infrastructure question is immediate: what documentation, monitoring, and audit capabilities do plans need to demonstrate that any payments to distribution partners are genuinely for services rendered and not for enrollment volume?

The Federal Court Ruling

#

A federal district court found that CMS lacks “ratemaking authority” over broker compensation and invalidated the regulations setting agent and broker compensation price caps. The ruling created regulatory uncertainty for the CY 2026 and CY 2027 contracting cycles. If CMS cannot set compensation caps, the primary tool the prior administration used to prevent bidding wars for broker loyalty is unavailable.

The practical effect is a compliance-in-limbo problem. Plans must contract with brokers for CY 2027 before the full regulatory landscape is settled. The court ruling removes one set of constraints. The CMS-4212-P proposed rule relaxes others. But the DOJ action and the AKS statutory framework impose constraints that no court ruling or CMS rulemaking can remove. Plans adopting aggressive compensation postures in response to the court ruling and the deregulation signal face the risk that their compensation structures become evidence in a future DOJ enforcement action.

The divergence between conservative and aggressive compliance postures is widening. Plans advised by outside counsel with FCA defense experience are maintaining compensation documentation and monitoring infrastructure regardless of CMS deregulation. Plans interpreting the regulatory environment as permissive are increasing broker incentives to compete for enrollment volume in the CY 2027 cycle. The DOJ case will determine which posture was correct.

The Senate Finance Investigation

#

Congressional oversight provides a third vector of pressure on the broker ecosystem, operating independently of both CMS rulemaking and DOJ enforcement.

The Senate Finance Committee has been investigating broker churning: the practice of switching beneficiaries between MA plans to generate a new commission on each switch. The investigative focus centers on the dual eligible and LIS population, which has access to a monthly Special Enrollment Period that allows plan switching outside the annual enrollment period. For brokers, each switch generates a commission. For the beneficiary, each switch disrupts provider relationships, prescription continuity, and care coordination. The monthly SEP, designed to give vulnerable beneficiaries flexibility, functions as a recurring revenue opportunity for agents with no corresponding benefit to the enrollee.

The political dynamic is notable. The investigation has bipartisan traction because predatory enrollment practices harm seniors in both Republican and Democratic districts. Congressional oversight functions as a counterweight to CMS deregulation: even if CMS loosens the rules, the committee’s investigative findings create a public record that supports future legislation. Whether the investigation leads to statutory changes or remains an oversight tool depends on the 119th Congress’s legislative bandwidth, which is constrained by the reconciliation process and other priorities (MCR-03.04).

The Coexistence Problem

#

The defining feature of the current broker regulatory environment is that enforcement risk and deregulation coexist. CMS may loosen rules through CMS-4212-P. The federal court may vacate compensation caps. But DOJ maintains its enforcement posture, the AKS statutory framework remains intact, and OIG continues to investigate marketing and enrollment practices.

Plans that interpret deregulation as permission to relax compliance infrastructure face a specific and quantifiable legal risk. The DOJ complaint against Aetna, Humana, Elevance, eHealth, GoHealth, and SelectQuote alleges conduct from 2016 through 2021, a period when the regulatory framework was less restrictive than what the Biden CMS subsequently imposed. The conduct DOJ is challenging was not prohibited by CMS rulemaking at the time it occurred. It was prohibited by the Anti-Kickback Statute and the False Claims Act, statutes that operate independently of CMS regulatory cycles.

The compliance infrastructure investment case is straightforward: build for the most restrictive interpretation of law because the consequences of underinvestment are existential. FCA treble damages on a large-scale broker steering case can reach hundreds of millions of dollars. CMS deregulation does not provide a defense to an AKS-based FCA claim. Plans that reduce compliance monitoring, relax documentation requirements, or increase broker incentives in reliance on the deregulation signal are making a bet that DOJ will not pursue them. The eHealth case suggests that bet has unfavorable odds.

Related Reading

#

MCR-03_04 Reading the Federal Regulatory and Legislative Calendar: What’s Coming in 2026–2027 MCR-07_01 Your Medicare Plan Is Changing: What to Expect in 2026 and 2027